CVRx, Inc.
10900 73rd Avenue N.
Suite 116
Maple Grove
Minnesota
55369
United States
Tel: 763-416-2840
Fax: 763-416-2841
Website: http://www.cvrx.com/
99 articles about CVRx, Inc.
-
CVRx Scores $113 Million in New Financing
8/9/2016
-
CVRx Raises $46 Million from Unnamed Investors
6/20/2016
-
CVRx, Inc. Announces That The First Two Patients Were Treated In The Phase III Pivotal Trial Evaluating BAROSTIM THERAPY For The Treatment Of Heart Failure
6/6/2016
-
CVRx, Inc. Announces Expedited Access Pathway Designation By FDA for Barostim Therapy For The Treatment Of Heart Failure In Order To Accelerate Access For US Patients
11/19/2015
-
CVRx, Inc. Barostim Therapy For Heart Failure Clinical Trial Results Presented In The Late-Breaking Clinical Session Of The ESC-Heart Failure 2015 Annual Conference
5/27/2015
-
CVRx, Inc. Barostim Therapy For Heart Failure Clinical Trial Results Presented In The Late-Breaking Clinical Trial Session Of The Heart Rhythm Society 2015 Annual Conference
5/26/2015
-
CVRx, Inc.Barostim Therapy For Heart Failure Clinical Trial Results Selected To Be Presented In The Late-Breaking Clinical Trial Session Of The Heart Rhythm Society 2015 Annual Conference
4/16/2015
-
CVRx, Inc.'s Failed Trial Leaves Man Facing Death
3/18/2015
-
CVRx, Inc. Barostim Therapy For Heart Failure Clinical Trial Results Presented In A Featured Clinical Research Session Of The American College of Cardiology Annual Conference
3/17/2015
-
CVRx, Inc. Barostim Therapy™ For Heart Failure Clinical Trial Results Selected To Be Presented In A Featured Clinical Research Session Of The American College Of Cardiology Annual Conference
2/2/2015
-
CVRx, Inc. Granted Humanitarian Device Exemption Approval From FDA For Barostim Neo Legacy Hypertension Therapy Device
12/16/2014
-
CVRx, Inc. Granted CE Marking Of The Barostim Neo System For Conditional MRI Compatibility
12/11/2014
-
CVRx, Inc. Announces First Successful Barostim Heart Failure Commercial Implants In Europe
10/7/2014
-
CVRx, Inc. Wins CE Mark Approval Of The Barostim Neo System™ To Treat Heart Failure
9/29/2014
-
CVRx, Inc. Secures $15 Million Growth Capital Facility From Silicon Valley Bank
9/22/2014
-
CVRx, Inc. Release: Barostim Therapy Projected To Be Cost-Effective In Treating Resistant Hypertension
1/7/2014
-
DaVita Gets in on $12 Million Round for CVRx, Inc.
11/1/2013
-
CVRx, Inc. Grabs Another $12 Million
10/30/2013
-
CVRx, Inc. Snags $29.6 Million
7/11/2013
-
CVRx, Inc. Launches HOPE4HF™ Clinical Trial Evaluating Barostim Neo™ in Heart Failure Patients
4/29/2013